Thrombolytic therapy has become an accepted part of the management of acute myocardial infarction. One agent with widespread use in this setting is streptokinase. We report the case of a 62-year-old man who experienced an anaphylactic reaction with cardiopulmonary arrest immediately after receiving streptokinase 1.5 million units iv administered for an acute anterior wall myocardial infarction. The patient had no history of prior exposure to streptokinase, chronic allergic reactions, or reactive airway disease. Five other cases of anaphylaxis to streptokinase are also reviewed.
Get full access to this article
View all access options for this article.
References
1.
ThayerCF. Results of a post marketing surveillance program on streptokinase. Curr Ther Res1981; 30: 129–40.
2.
McGrathKGZeffrenB.AlexanderJ., Allergic reactions to streptokinase consistent with anaphylactic or antigen-antibody complex mediated damage. J Allergy Clin Immunol1985; 76: 453–7.
3.
Gruppo Italiano per lo Studio Della Streptochinasi Nell'Infarcto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet1986; 1: 397–401.
NoelJ.RosenbaumLHGangadharanV., Serum sickness like illness and leukocytoclastic vasculitis following intracoronary arterial streptokinase. Am Heart J1987; 113: 395–7.
8.
ThompsonRFStrattonMAHeffronWA. Hypersensitivity vasculitis associated with streptokinase. Clin Pharm1985; 4: 383–4.
McGrathKGPattersonR.Anaphylactic reactivity to streptokinase. JAMA1984; 252: 1314–7.
11.
JarvinenP.AromaaU.RoihaM.AspK.Streptokinase and concomitant oral anticoagulants in the treatment of deep venous thrombosis. Klin Wochenschr1978; 56: 801–4.
12.
CarterBLJonesMEWaickmanLA. Pathophysiology and treatment of deep venous thrombosis and pulmonary embolism. Clin Pharm1985; 4: 279–96.
13.
BellWRMeekAG. Guidelines for the use of thrombolytic agents. N Engl J Med1979; 301: 1266–70.
14.
KakkarVVFlancC.O'SheaMJHoweCTClarkeMB. Treatment of deep venous thrombosis with streptokinase. Br J Surg1969; 56: 178–83.
15.
AriszL.TegzessAMDonkerAJMMeuerS.SibingaCTSVan Der HemGK. The use of streptokinase in obstructed arterio-venous shunts. Postgrad Med J1973; 49 (suppl 5): 99–102.
DykewiczMSMcGrathKGDavisonR., Identification of patients at risk for anaphylaxis due to streptokinase. Arch Intern Med1986; 146: 305–7.
18.
ReimerKALoweJERasmussenMMJenningsRB. The wavefront phenomenon of ischemic cell death 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation1977; 56: 786–93.
19.
RosowCEMossJ.PhilbinDMSavareseJJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology1982; 56: 93–6.
20.
GraverMLRobertsonDALeviR.BeckerCGWekslerBBGayWA. IgE-mediated hypersensitivity in human heart tissue: Histamine release and functional changes. J Allergy Clin Immunol1986; 77: 709–14.
21.
KalsnerS.RichardsR.Coronary arteries of cardiac patients are hyper-reactive and contain stores of amines: A mechanism for coronary spasm. Science1984; 223: 1435–7.
22.
WolffAALeviR.Histamine and cardiac arrhythmias. Circ Res1986; 58: 1–16.
JacobsRLRakeGWFournierDCChiltonRJCulverWGBeckmannCH. Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade. J Allergy Clin Immunol1981; 68: 125–7.
25.
GreenbergerP.PattersonR.KellyJ.StevensonDDSimonR.LiebermanP.Administration of radiographic contrast media in high-risk patients. Invest Radiol1980; 15: S40–3.
26.
JohnsonESCregeenRJ. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex. Drugs1987; 33: 298–311.
